Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN.c upcoming milestones

<< Previous

Bullboard Posts

Next >>

Post by StockDoctor101on Feb 03, 2023 2:46pm

167 Views

Post# 35265605

AGN.c upcoming milestones

Lot of upcoming milestones which could get AGN moving. Look out for data from phase 1 of the DMT study in Q2 of this year along with the beginning of a phase 2b IPF study for chronic cough also set for Q2.

The global stroke treatment market could also reach $15B by 2027, which adds to the significant upside for AGN.

<< Previous

Bullboard Posts

Next >>

TELUS adds 347K customers in Q3